Prognostic Factors in Malignant GI Bleeding Treated With Hemostatic Powder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03066700|
Recruitment Status : Not yet recruiting
First Posted : February 28, 2017
Last Update Posted : March 1, 2017
|Condition or disease||Intervention/treatment|
|Death||Device: Hemostatic powder|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Prognostic Factors of Outcome in Patient With Malignant Gastrointestinal Bleeding Treated With a Novel Hemostatic Power|
|Estimated Study Start Date :||March 1, 2017|
|Estimated Primary Completion Date :||June 1, 2017|
|Estimated Study Completion Date :||August 31, 2017|
The patients with GI bleeding from tumor and received Hemospray as a hemostasis method.
Device: Hemostatic powder
HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
Other Name: HemosprayTM
- Mortality rate [ Time Frame: 6 months ]Death rate after applying HemosprayTM
- Rebleeding rate [ Time Frame: 30 days ]Bleeding from tumor after applying HemosprayTM
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03066700
|Contact: Rapat Pittayanonfirstname.lastname@example.org|